sur Biophytis (EPA:ALBPS)
Biophytis Announces Combined General Meeting for April 2024
Biophytis SA, a clinical-stage biotechnology company focusing on age-related disease therapeutics, declared it will conduct its Combined General Meeting (CGM) on April 2, 2024. The meeting is scheduled to take place at Sorbonne Université in Paris, with details published in the Bulletin des Annonces Légales Obligatoires.
The company encourages shareholders to vote in advance using several methods available, including postal votes, proxy votes through the Chairman, or the VOTACCESS platform, with deadlines set for March 30 and April 1, 2024, respectively.
Biophytis is known for its work on developing treatments targeting the degenerative processes of aging and improving patients' lives with age-related conditions. The company's notable drug candidate, RuvembriTM, is under development for several age-related diseases, showing promising results in clinical studies.
R. H.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biophytis